The Federal Trade Commission recently announced the US antitrust approval for Abbott Laboratories' (ABT) acquisition of Alere (ALR).
Mastercard (MA) posted net income of $1.2 billion in 2Q17, reflecting a substantial increase of 20% from its 2Q16 net income.
Dow Chemical's (DOW) Performance Materials and Chemicals (or PM&C) segment is the company's third-largest revenue generator, accounting for 18.5% of the company's revenue.
Anthem, a US health insurance company, was the S&P 500's top loser on September 12. Anthem fell 3.4% to $189.24—the biggest fall in ten months.
Once the SEC approves the proxy, a vote is scheduled. Usually, the last condition for a deal is the vote of the target shareholders.
GlaxoSmithKline’s (GSK) Pharmaceuticals segment declined substantially in 2015 due to the divestment of its oncology business to Novartis (NVS) in March 2015.
In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Abraxane’s fiscal 2018 net product sales of around $1.0 billion.
In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) GeneSight reported revenues of $28.8 million, which is a YoY growth of 54% and a sequential growth of 12%.
Boston Scientific (BSX) has estimated the market opportunity in pancreaticobiliary disease to be $1.4 billion in 2018 and $1.7 billion by 2021.